National Leasing Director for Army & Air Force Exchange Service, a division of the Department of Defense. Management of Landlord Rep Brokers, oversight of Retail Lifestyle Center lease negotiations, strategic planning, Base/Post Retail Planning, RCI Leases, Community Development Initiative manager. Manages leasing administration and space development activities for shopping centers and other retail concepts world-wide. Negotiates with developers, retailers, attorneys and construction personnel to accomplish projects in accordance with corporate guidelines. 111 - libality insurace - OMER- Yo stock crash hunu ko main karan thiyo... 1. Company ko ausodhi le jun kisim le billing garna pako thiyo...tyo 'subidha' Jan 1st 2018 bata samapta vayo. Tes paxi confusion ayo...sabai hospital haru ma...ausodhi use kasari garni ra payment kasari garni vanera. Tyo 'subidha' bandha vayae ko karan le gardha...stock crash vayo. Tara recently, like last week or this week...k vayo vane...company le tyo subidha feri payo...HIB ma query ayera paxi approve vako jasto ghatna ghatyo vanda pani hunxa...H1B ma query ayeko le...cosustant ko jagir gayo...tara paxi H1B approve vayo...tara consultant le October 1st 2018 samman kurnu paryo vaneko jastai gari..aba yo company le pani...tyo ausodhi ma feri 2 years lai subidha payeko xa....starting October 1st 2018....Aba question is...k hunxa ta Jan 1st 2018 dekhi September 31st 2018 samman tyo ausodhi ra company ko 'health'...Well, I don't know k hunxa...but yo ta pakka vai sakyo ki...Oct 1st bata yo company le subidha feri pako xa.... "On March 23, 2018, President Donald J. Trump signed into law the Consolidated Appropriations Act, 2018 (the “Act”). A bipartisan-supported provision in the Act extends pass-through reimbursement status for a small number of drugs used during procedures performed on Medicare Part B fee-for-service patients for an additional two years, effective October 1, 2018 through September 30, 2020. The drugs that qualify for this extension are those for which previously existing pass-through reimbursement status expired on December 31, 2017 and which became included as part of the packaged procedural payment as of January 1, 2018. OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%, the U.S.-marketed drug product of Omeros Corporation, is one of the drugs for which pass-through reimbursement status was extended pursuant to the Act. As a result of this extension, each of these drugs, for the two-year period beginning October 1, 2018, will receive separate payment at a rate of average sales price, or ASP, plus six percent, consistent with almost all other physician-administered drugs that come off pass-through status." https://www.sec.gov/Archives/e... Ok aba...yo company le...varkharai...less than a year ago....$22.75 per share ma stock becheko thiyo...'experienced institutional investors' haru lai... Omeros (NASDAQ:OMER) closes its public offering of 3M shares of common stock at $22.75 per shares. Net proceeds of ~$63.6M will be used for general corporate purposes. https://seekingalpha.com/news/... Uni haru le pakkai pani yo stock...$22.75 vanda pani high price hunxa vanera kineko hola....ki kaso solta solti haru? let me know what ya'll think..maile chahi..ali ali buy buy gari rako xu hai...feri vanena na vannu paxi...re kya...ahile stock price less than $12 xa ...